US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
Adds statement from Outsourcing Facilities Association in paragraph 6
FDA to review if there's a shortage of tirzepatide
Outsourcing Facilities Association lawsuit led to FDA reconsideration
Shortages of Lilly and Novo Nordisk drugs drive demand for compounded versions
By Brendan Pierson
Oct 11 (Reuters) -The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's LLY.N blockbuster weight loss and diabetes drugs.
The agency said in a court filing it would now allow compounding pharmacies and facilities to keep providing the drugs while it reviews whether there is a shortage of their active ingredient. The compounding versions of the drugs are cheaper for patients than the brand-name versions.
The decision was in response to a lawsuit brought on Monday by the Outsourcing Facilities Association, a compounding industry group. After the FDA's decision on Friday to reconsider, U.S. District Judge Mark Pittman in Fort Worth, Texas put the lawsuit on hold.
The Sept. 30 decision by the FDA endangered the ability of compounders to sell versions of Lilly's weight loss drug Zepbound and diabetes drug Mounjaro. The FDA decision removed their active ingredient, tirzepatide, from its list of drugs experiencing shortages.
That would have cut off access for many patients to the compounded versions they relied on during the shortage, which are cheaper than the brand name drugs. Insurers generally cover drugs like tirzepatide for diabetes, but many do not cover them for weight loss.
Outsourcing Facilities Association Chairman Lee Rosebush said in a statement the group was "greatly relieved, for our members and the many patients that they serve, that the FDA has agreed to reconsider its decision."
Shortages of Lilly's drugs and competitors like Novo Nordisk's NOVOb.CO Ozempic have fueled demand for compounders' versions. Mounjaro had been on the FDA's list of drugs in short supply since late 2022, while Zepbound was added in April.
Compounded drugs, unlike conventional brand-name or generic drugs, are sold without first getting FDA approval. Compounding pharmacies may create drugs to fill prescriptions for specific patients, while so-called outsourcing facilities prepare compounded drugs in bulk.
Federal regulations allow compounded versions of an FDA-approved drug to be sold to meet demand if the drug is in short supply. If there is no shortage of a drug, compounded versions of it cannot be made regularly or in large amounts.
The Outsourcing Facilities Association claimed in its lawsuit the FDA removed tirzepatide from its shortage list even though it remained in short supply.
Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed lawsuits against sellers falsely claiming to sell FDA-approved versions of the drug.
The active ingredient in Novo Nordisk's drugs, semaglutide, remains on the FDA's shortage list.
Reporting By Brendan Pierson in New York; Editing by David Gregorio and Chris Reese
Últimas noticias
Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.
Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.
Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.
